Pet King Brands Announces Appointment of Chief Revenue Officer
AUSTIN, Texas, April 23, 2025 /PRNewswire/ — Pet King Brands, a pioneering leader in veterinarian-recommended enzymatic pet health products, including ZYMOX Dermatology and Oratene Brushless Oral Care, announces the appointment of its new Chief Revenue Officer (CRO), Ish Medeles.
Medeles brings 35 years of technical sales and marketing experience to oversee all aspects of the company's revenue generation strategy while driving top-line growth. Effective immediately, Medeles will lead sales, marketing and customer success teams to deliver a unified, high-performance revenue function for the brand.
'Ish's valuable expertise and strategies are a real asset to Pet King Brands as we enter a new phase of growth,' said Pamela Bosco, President and Founder of Pet King Brands. 'Ish's proven track record in both global trade and sector-specific strategies will help us achieve our long-term goals, as well as strengthen our position in an increasingly competitive market.'
For the last 14 years, Medeles was Vice President of Butadiene and Buten-1 at TPC Group. His extensive experience in the oil and gas industry also included roles at Texaco, Chevron Chemical, BP, Samsung, and INEOS where he managed commercial activities, drove business growth and led strategic initiatives. He studied chemistry at the University of Houston and pursued further studies in International Trade at the University of Oklahoma.
For more information about ZYMOX or Pet King Brands, visit www.zymox.com. If you are a member of the media and would like to request more information, hi-res images or an interview with Pet King Brands founders, please contact Kerry Sutherland at K. Sutherland PR, (775) 360-6101 or kerry@ksutherlandpr.com.
About Pet King BrandsPet King Brands, proud sponsors of The Westminster Kennel Club's 149th Dog Show and makers of ZYMOX® Ear and Skin, Oratene® Brushless Oral Care, Equine Defense®, and ZYLAFEN™ products, is a leader in veterinarian-approved pet products made in the USA. Focused on the health and wellness of small and large animals of all ages, the products utilize the power of the LP3 Enzyme System and have been resolving ear, skin and oral conditions for over 25 years. Led by President and Founder Pamela Bosco, with the help of her bioscientist brother, Michael Pellico, Pet King Brands has revolutionized the way people care for animals' ears, skin and mouths, offering solutions that are gentle, easy to administer and free of harsh chemicals and antibiotics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
2 hours ago
- The Sun
Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha
HONG KONG SAR - EQS Newswire - 2 July 2025 - On June 27, 2025, Uni-Bio Science Group Limited (the 'Group')grandly held a new medical aesthetics product launch event in Changsha, releasing the high-end series GeneQueens of 肌顏態® and the medical device brand 金因敷®. Many experts, KOLs and partners attended the event. This launch not only showcased the Group's achievements in R&D, but also marked the comprehensive layout in the 'drug, medical device and Aesthetics' field. 1、 High-end medical aesthetics: GeneQueens series At the launch, the Group unveiled the high-end series of 肌顏態® -——GeneQueensTM (Human-Sequence Triple Protein Repair & Balance Ampoule). which functions on skin repair and anti-aging. By activating cell regeneration, it helps users restore their youthful and healthy skin condition. GeneQueensTM sets a new standard for anti-aging and repair by adding three core ingredients in sufficient quantities. Skbrella FN, as a key ingredient for cell repair, can accelerate the healing of skin wounds and promote the adhesion and migration of new cells. III Collagen strongly fills the skin structure, significantly enhancing elasticity and firmness. XVII Collagen can strengthen the connection between the epidermis and dermis, and consolidate the youthful foundation of the skin. In addition, GeneQueens adopts a sterile and preservative-free formula, relying on high-purity raw materials and patented technology, providing users with an 'instant enjoyment' precise and efficient experience. Its unique formula and outstanding efficacy were highly recognized by many experts on the spot. 2、金因敷 showcased a variety of new products Meanwhile, the Group also launched several new products of its medical device brand - 金因敷®, focusing on the professional repair field of medical aesthetics. 金因敷® complies with strict clinical trials and quality inspections to ensure its safety and effectiveness. The product adopts a high-purity non-allergenic formula, which can moisturize and accelerate wound repair. It also uses an exclusive cooling technology to relieve postoperative swelling and pain, providing a professional solution for sensitive skin and post-medical procedure care. 3、The latest research data was presented at CSD2025 It is worth mentioning that 肌顏態® also showcased the research data of 'The Efficacy Study of Fibronectin in the Repair of Skin Barrier Damage for the post-medical procedure' jointly conducted with the Cosmetics Testing Center of the Dermatology Hospital of Southern Medical University in the poster area of the 30th Academic Conference of the Chinese Medical Association (CSD2025). This is not only an endorsement of the Group's research capabilities, but also provides experts and scholars in the industry with an opportunity to gain a deeper understanding of the 肌顏態® technology and products. As an annual grand event in the field of dermatology and venereology in China, CSD2025 brings together authoritative experts and scholars in dermatology across the country, presenting multi-dimensional academic achievements and exchanges of ideas. The poster area is one of the core venues of the academic annual conference. Posters are not only an important way for researchers to showcase their scientific research achievements, but also a key link in promoting the dissemination of academic ideas and the feedback of clinical practice. 4、Academic speeches by several experts Several clinical experts at the launch further recognized the significant clinical value of 肌顏態® and 金因敷®. The experts highlighted that 肌顏態®' s patented ingredient, Skbrella FN, demonstrates immense potential in improving damaged sensitive skin barriers, reducing inflammatory erythema, alleviating discomfort sensations such as burning, tightness and itching, as well as enhancing post-laser repair and healing. In the clinical observations over the past few months, many patients treated with 肌顏態® have achieved remarkable therapeutic effects. The symptoms of anesthetic allergy have been rapidly relieved, the inflammatory pigmentation post-laser has significantly improved, the skin barrier has been repaired, and the patient satisfaction rate is extremely high. 金因敷® can effectively reduce redness, swelling and pain for post-medical procedures, accelerate wound healing and shorten the recovery time. Photo 1: 肌顏態 use case sharing by Professor Shi Ge, Director of the Department of Plastic Surgery of the Sixth Affiliated Hospital of Sun Yat-sen University; Photo 2: 肌顏態 use case sharing by Professor Ge Lan, from The First Affiliated Hospital of Army Medical University; Photo 3: Fibronectin clinical trial results sharing by Professor Ye Li, Head of Cosmetics Testing Center at Dermatology Hospital of Southern Medical University; Photo 4: Mr. Du Wei, CEO of Cosmetics News & Cosmetics Business Online, analyzes cosmetics industry development trends 6、The signing ceremony reflects the market potential Mr. Zhao Zhigang, CEO of Uni-Bio Science Group, emphasized: ' We have always adhered to the standards of biopharmaceuticals in creating skin care products. The release of GeneQueens and 金因敷 is an important milestone in building the 'Drugs, Medical device and Aesthetics' strategy and creating a full-cycle skin care solution, aiming to meet consumers' increasingly refined skin health needs. ' Furthermore, Ms. Liu Yihua, President of Global Cosmetics Group, attended the launch as an important guest. Uni-Bio Science Group and Global Cosmetics Group have jointly established a medical research co-creation biological platform. Utilizing gene-editing biosynthesis technology, the platform has launched Skbrella FN – a highly bioactive recombinant human fibronectin known as '皮優理'. The launch also witnessed a grand strategic signing ceremony. The Group has achieved in-depth cooperation with many well-known medical aesthetics chain institutions and well-known agents. This signing is not only a high recognition of the quality and market potential of GeneQueens and 金因敷®, but also a key step for the Group to accelerate commercialization and expand channels. Through strong alliances with leading channel partners, the Group will reach the core consumers and ensure the rapid release of huge commercial value. The successful holding of this launch not only marks a crucial step for the Group in medical aesthetics and medical devices, but also demonstrates the Group's in-depth layout and forward-looking vision in the 'Drugs, Medical device and Aesthetics' strategy. In the future, the Group will continue to be guided by technology and oriented towards clinical value, accelerate product innovation and technological upgrading, constantly enrich pipeline, and meet the growing market demands.
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Medline named Prime Vendor by Wachusett Healthcare
East Coast provider of skilled nursing and rehabilitative services taps into Medline's supply chain and clinical portfolio NORTHFIELD Ill., July 1, 2025 /PRNewswire/ — Medline today announced a new Prime Vendor agreement with skilled nursing and rehabilitative services provider Wachusett Healthcare. As part of the agreement, Wachusett Healthcare's facilities will choose from Medline's extensive portfolio of medical products and supplies, including Medline's skin health products. The East Coast-based organization will also receive accompanying skin health guidelines, educational programs and evidence-based online training courses for continuing education in skin and wound care via Medline University, as well as in-servicing through Medline's team of clinicians and skin health specialists. 'At Wachusett Healthcare, we are always striving to enhance the quality of care and operational excellence across our facilities. Our partnership with Medline represents a strategic alignment with a leader in healthcare supply chain solutions,' said Steven Vera, Chief Executive Officer, Wachusett Healthcare. 'It will allow us to streamline our procurement process, ensure consistent access to high-quality products, and ultimately support our staff in delivering exceptional care to our residents.' Said Brendon Anderson, corporate accounts director for Medline Long-Term Care: 'Wachusett Healthcare is committed to providing a safe and compassionate care environment. We will support them in their commitment by ensuring a consistent supply of high-quality medical products that positively impacts Wachusett's care delivery needs. We are honored to be their Prime Vendor.' Learn how Medline works with long-term care providers to improve clinical, financial and operational outcomes at About MedlineMedline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs more than 43,000 people worldwide and operates in more than 100 countries and territories. To learn more about how Medline makes healthcare run better, visit FacebookTwitterLinkedInYouTube
Malaysian Reserve
7 hours ago
- Malaysian Reserve
XTEND Reality Inc. Debuts New U.S. Headquarters and Drone Production Facility in Tampa, Driving Innovation and National Security
New facility strengthens America's domestic drone production capacity while bringing high-tech jobs and investment to Florida TAMPA, Fla., July 1, 2025 /PRNewswire/ — XTEND Reality Inc. (XTEND), a global leader in human-guided autonomous drone systems, officially debuted its new U.S. headquarters and production facility today in Tampa, Florida. The ribbon-cutting event brought together federal, state and local leaders, as well as military personnel, to celebrate a major milestone in advancing American drone capabilities and bolstering regional economic development. The new facility will manufacture and integrate XTEND's advanced drone systems to support critical U.S. defense missions. The opening comes as federal leaders intensify their push for domestically produced drone technologies that reduce foreign reliance and strengthen national security. 'We are not just building drones, we are building capabilities, resilience and trust,' said XTEND Chief Executive Officer and Co-founder Aviv Shapira. 'This facility marks a new chapter for XTEND in the United States and reflects our commitment to delivering the most advanced, mission-ready systems to our customers. We're proud to establish our U.S. headquarters in Tampa and grateful for the strong support from local, state and federal partners as we continue to scale our operations.' XTEND was founded in 2018 by brothers Aviv and Matteo Shapira in partnership with Rubi Liani. Prior to establishing XTEND, the Shapira brothers co-founded Replay Technologies, which was acquired by Intel in 2016 for $175 million. 'Our systems are designed to give operators unprecedented control, safety and performance in the most demanding environments,' said XTEND CTO and Co-Founder Rubi Liani. 'This new facility enables us to bring advanced engineering and innovation directly to the U.S. market, allowing for rapid integration, customization and deployment. It's a critical step in our mission to redefine human-machine collaboration in defense and national security.' 'Establishing a U.S. headquarters and production facility is more than just a business expansion, it's a commitment to building enduring partnerships that strengthen America's defense innovation ecosystem,' said XTEND Vice President and U.S. General Manager Roy Levy. 'This facility is not just about delivering cutting-edge systems, it's about ensuring speed, reliability and integration at the pace of mission demand. XTEND is here to deliver solutions that work when it matters most.' 'This milestone represents the realization of XTEND's vision to bring our groundbreaking technologies closer to the U.S. defense ecosystem,' said Dr. Peter Kash, XTEND Chairman of the Board. 'With this facility, we're laying the foundation for sustained growth, high-tech job creation and meaningful contributions to America's security and industrial capabilities. I'm incredibly proud of the team that made this moment possible, amplifying the connectivity of Florida and the future of AI and Robotics.' XTEND's U.S. facility represents a major step in expanding U.S.-based production capacity and supporting the growing demand for advanced drone systems across the defense and public safety sectors. While focused on delivering Group 1 drones under contract for the U.S. Department of Defense, manufacturing will eventually expand to other critical drone components such as communication modules, motors and controllers to serve the country's broader drone industry. The site is expected to generate dozens of new jobs over the coming years and further Florida's role as a hub for aerospace and defense systems manufacturing. About XTEND Reality Reality Inc. is a pioneering defense technology company specializing in AI-assisted, human-guided drone systems designed to transform tactical operations across defense, public safety, and private security sectors. Our mission is to enhance remote operators' combat impact with cost-effective, AI-assisted tactical Unmanned Aerial Systems (UAS). At the core of our innovation is the patented XTEND Operating System (XOS), which seamlessly integrates human decision-making with machine autonomy. This platform empowers operators to conduct complex missions remotely with ease, controlling teams of multi-mission robots and enabling autonomous sub-tasks while retaining high-level decision-making in human hands. Founded in 2018 and headquartered in Tel Aviv, Israel, XTEND has expanded its operations to the United States, with a significant presence in Florida. Our team comprises experts in aeronautics, flight algorithms, mechanical design, system architecture, UX/UI, and operations & integration, all dedicated to pioneering advancements in human-machine teaming. XTEND's systems are battle-proven and operationally deployed worldwide, continuously evolving to meet the demands of modern warfare and public safety operations. By fusing cutting-edge technology with human intuition, XTEND is committed to delivering the future of tactical UAS control, ensuring mission success and operator safety. Photo – – – – – – View original content:
